ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 573,65
-0,77%
Dow Jones
40 211,72
0,00%
DAX
18 500,95
-0,53%
Brent Oil
82,895
-1,71%
Bitcoin
63 800,00
-1,63%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
24/07/202310h00Business WireTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars PartnershipNYSE:TEVATeva Pharmaceutical Industries Ltd
05/07/202322h30Business WireTeva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
01/07/202311h37Business WireTevas dritte Zwischenanalyse der PEARL-Real-World-Studie zu AJOVY® (Fremanezumab) zeigt anhaltende langfristige Wirksamkeit bei der Verringerung von Häufigkeit, Dauer und Schwere der Anfälle bei Patienten mit chronischer und episodischer MigräneNYSE:TEVATeva Pharmaceutical Industries Ltd
01/07/202300h13Business WireLes 3 de Tevard Analyse intermédiaire de l'étude PEARL en situation réelle sur AJOVY® (fremanezumab) révèle une efficacité soutenue à long terme dans la réduction de la fréquence, de la durée et de la sévérité des crises chez les patients attNYSE:TEVATeva Pharmaceutical Industries Ltd
30/06/202318h30Business WireTeva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraineNYSE:TEVATeva Pharmaceutical Industries Ltd
20/06/202313h40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
15/06/202322h02Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
15/06/202314h00Business WireTeva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in PatientsNYSE:TEVATeva Pharmaceutical Industries Ltd
13/06/202300h40Dow Jones NewsCorrection to Teva Pharmaceutical Headline, ArticleNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/202322h44Dow Jones NewsTeva Pharmaceutical Agrees to Pay $1.41 Billion to Settle Kentucky Price-Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/202322h00Business WireTeva Reaches Agreement With Kentucky to Settle the State’s Price Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
12/06/202313h00Business WireAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®NYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/202318h33Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NYSE:TEVATeva Pharmaceutical Industries Ltd
09/06/202316h39Dow Jones NewsNY AG Lands Final Approval for $17.3 Billion Opioid SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202315h27Dow Jones NewsTeva Pharma Reaches Opioid Settlement With Nevada, the Final State to Resolve ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/06/202314h30Business WireTeva Concludes Nationwide Opioids Settlement AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
06/06/202314h00Business WirePhil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma ManagementNYSE:TEVATeva Pharmaceutical Industries Ltd
02/06/202322h30Business WireTeva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
24/05/202322h29Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:TEVATeva Pharmaceutical Industries Ltd
24/05/202322h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
20/05/202317h00Business WireTeva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
18/05/202314h30Business WireTeva Launches New “Pivot to Growth” StrategyNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202314h00Business WireAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202322h05Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/05/202313h00Business WireTeva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202313h00Business WireTeva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of ScheduleNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202314h30Business WireU.S. Mental Health Access Program Expands Medicine Donation to Seven New StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva et MedinCell annoncent l'approbation par la FDA américaine de UZEDY™ (risperidone), un antipsychotique sous forme de suspension injectable sous-cutanée à libération prolongée pour le traitement de la schizophrénie chez l'adulteNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/202314h35Business WireTeva to Launch New Growth Strategy at Investor DayNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

LSE
0AH7
Baywa
LSE
0QLT
Graubuendner Kantonalbank
NASDAQ
DOX
Amdocs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés